Free company analysis covering financials, risk flags, competitive position, and opportunity scoring. Global leader in structural heart disease therapies with approximately $6B revenue. Transcatheter aortic valve replacement (TAVR) franchise anchored by the Sapien platform. Spun off Critical Care (to Baxter) to sharpen focus on structural heart and heart failure, with EVOQUE tricuspid and PASCAL platforms expanding the addressable market.
Global leader in structural heart disease therapies with approximately $6B revenue. Transcatheter aortic valve replacement (TAVR) franchise anchored by the Sapien platform. Spun off Critical Care (to Baxter) to sharpen focus on structural heart and heart failure, with EVOQUE tricuspid and PASCAL platforms expanding the addressable market.
Free 1-page brief delivered in minutes. Full 20-page report available for purchase.
Get Free Brief → Buy Full Report ($39.20 launch)